We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
Quarterly Results: Instrument, reagent disc and hematology reagent revenues increased by an aggregate of $1.0 million, or 4%, for the quarter ended December 31, 2008, over the same
“As previously announced, reduced demand in our Early Development segment from a combination of a lower level of new project initiations and increased project delays in our toxicology
High-end tests such as genetics and molecular biology, which are labour-intensive, are sent to India as they can be serviced at nearly one-eighth the costs of developed markets.
Todd Motto, vice president of sales and marketing, Meridian Bioscience commented, “Following a thorough evaluation of the Australian and Argentinean markets, it is clear that Immuno Pty and
Kennedy continues to serve as a member of the board of directors of IVAX. Kennedy has also informed IVAX that he plans to maintain a large equity interest
Perrey joined the company from Third Wave/Hologic Japan and previously held various positions in the Japanese in-vitro diagnostic industry (especially in infectious diseases segments). He was also involved
Adjusted net income, excluding stock option expense and certain other expenses, increased 3% to $1,124 million in the fourth quarter of 2008 compared to $1,088 million in the
Perez comes to Cubist in 2003 as senior vice president, sales and marketing, and led the launch of Cubicin. “Rob’s commercial and operational experience will be particularly helpful
“Allan has played an instrumental role in the development of our noninvasive prenatal diagnostic division, including serving as the principal investigator in a screening study to clinically assess
Matthias M. Baltisberger, Site Head Roche Basel, commented: “The location for an investment is not chosen for sentimental reasons. So an important criterion in selecting the site for